Inhibikase Therapeutics Announces Closing Of $10 Million Concurrent Registered Direct Offering And Private Placement Priced At A Premium To Market Under Nasdaq Rules

Inhibikase Therapeutics Inc IKT:

• INHIBIKASE THERAPEUTICS ANNOUNCES CLOSING OF $10 MILLION CONCURRENT REGISTERED DIRECT OFFERING AND PRIVATE PLACEMENT PRICED AT A PREMIUM TO MARKET UNDER NASDAQ RULES